Central Nervous System News and Research

RSS

New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today reported that a new clinical study shows that its investigational compound CXB722 has potential as a novel anxiolytic, demonstrating a significant effect on both endocrine and cardiovascular biomarkers associated with stress.

13 Jan 2010

MedGenesis Therapeutix enters into license agreement with Amgen

MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below.

12 Jan 2010

Paragon Biomedical launches second phase of restructuring and growth plan for worldwide operations

Paragon Biomedical, Inc. announced today that it has launched the second phase of its restructuring and growth plan for worldwide operations. Gena Reed, Paragon's Founder and Chief Executive Officer, said the strategy will build upon the company's strengths in its key therapeutic areas and regions.

12 Jan 2010

BIDMC scientists identify new pathway to address the problem of photophobia during migraines

Ask anyone who suffers from migraine headaches what they do when they're having an attack, and you're likely to hear "go into a dark room." And although it's long been known that light makes migraines worse, the reason why has been unclear.

11 Jan 2010

Chinese researchers become the world's fifth most prolific contributors to regenerative medicine

Chinese researchers have become the world's fifth most prolific contributors to peer-reviewed scientific literature on clock-reversing regenerative medicine even as a skeptical international research community condemns the practice of Chinese clinics administering unproven stem cell therapies to domestic and foreign patients.

8 Jan 2010

New genetic findings may lead to better interventional therapies for obsessive compulsive disorders

A collaboration between the University of Massachusetts Medical School, the Cummings School of Veterinary Medicine at Tufts University and the Broad Institute at the Massachusetts Institute of Technology has identified a genetic locus on canine chromosome 7 which coincides with an increased risk of obsessive compulsive disorder (OCD) susceptibility.

7 Jan 2010

Researchers identify new approach to eliminate side effects of drugs

Researchers at the Stanford University School of Medicine have taken an early step toward identifying a new approach to drug discovery that may eventually yield drugs with fewer side effects.

7 Jan 2010

EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124

EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe.

6 Jan 2010

Erectile dysfunction linked to RLS in older men

A study in the Jan. 1 issue of the journal Sleep shows that erectile dysfunction was more common in older men with restless leg syndrome (RLS) than in those without RLS, and the magnitude of this association increased with a higher frequency of RLS symptoms.

3 Jan 2010

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

30 Dec 2009

NeurAxon closes the sale of $8.75 million of unsecured subordinated convertible debentures

NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed the sale of approximately $8.75 million of unsecured subordinated 2.0% convertible debentures that are convertible under specified circumstances into existing class B preferred shares.

29 Dec 2009

Emerald BioStructures engineers new allosteric small molecule modulators of the PDE4 enzyme

Emerald BioStructures (formerly deCODE biostructures) announced today a publication in the December 27, 2009 advance online issue of Nature Biotechnology, detailing the application of structure-based drug design (SBDD) to engineer new allosteric small molecule modulators of the enzyme phosphodiesterase-4 (PDE4), with reduced side effects. According to the paper, the researchers established the structural basis of PDE4 regulation through crystal structures of the PDE4 regulatory domain in contact with small molecules.

29 Dec 2009

Nanoscaffolds could play a central role in tissue and organ reconstruction

Researchers from the University of Hong Kong and the Massachusetts Institute of Technology have published a study in the current issue of Cell Transplantation (18:9), now freely available on line at http://www.ingentaconnect.com/content/cog/ct, that explores ways to successfully keep stem cells "forever young" during implantation by slowing their growth, differentiation and proliferation.

28 Dec 2009

Publication validates company's structure-based approach for addressing undruggable targets

28 Dec 2009

Learning disabilities: Understanding the problem and managing the challenges

"Trying to address learning disabilities with innovative teaching methods and creative school financing is not the answer," said Etta Brown, a licensed educational psychologist, veteran social worker and author of "Learning Disabilities, Understanding the Problem and Managing the Challenges" from Langdon Street Press (www.understandingld.com).

24 Dec 2009

Novel discovery offers hope for patients with common brain tumor

Biomedical researchers at the University of Central Florida have found a protein that could hold the key to treating one of the most common and aggressive brain tumors in adults.

23 Dec 2009

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase I clinical study demonstrating ITI-007, the Company's lead antipsychotic drug, interacts with important targets in the living human brain. These key targets are critical to drug action in many neuropsychiatric and related disorders.

21 Dec 2009

Central Nervous System News and Research

New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic

MedGenesis Therapeutix enters into license agreement with Amgen

Paragon Biomedical launches second phase of restructuring and growth plan for worldwide operations

BIDMC scientists identify new pathway to address the problem of photophobia during migraines

Chinese researchers become the world's fifth most prolific contributors to regenerative medicine

New genetic findings may lead to better interventional therapies for obsessive compulsive disorders

Researchers identify new approach to eliminate side effects of drugs

EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124

Erectile dysfunction linked to RLS in older men

FDA accepts NDA review for new anticonvulsant drug

NeurAxon closes the sale of $8.75 million of unsecured subordinated convertible debentures

Emerald BioStructures engineers new allosteric small molecule modulators of the PDE4 enzyme

Nanoscaffolds could play a central role in tissue and organ reconstruction

Publication validates company's structure-based approach for addressing undruggable targets

Learning disabilities: Understanding the problem and managing the challenges

Novel discovery offers hope for patients with common brain tumor

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

UAB professors honored for scientific contributions and outstanding mentorship

First IOF Regional Osteoporosis Meeting in the Asia Pacific region

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Event guide: The 7th CNS Drug Delivery Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News